Study: Weight‑loss injections linked to subtle changes in taste, appetite

A study of people taking prescription weight‑loss injections including Wegovy, Ozempic and Mounjaro found that about one in five users reported changes in how food tastes, and those changes were associated with altered hunger, fullness and food cravings.

Researchers in Germany surveyed 411 current users of the medications and found 21.0 percent reported that food tasted sweeter and 22.6 percent reported that food tasted saltier than before treatment. The study population was 69.6 percent female; 148 were taking Ozempic, 217 Wegovy and 46 Mounjaro. Median treatment durations reported were about 43 weeks for Ozempic, 40 weeks for Wegovy and 47 weeks for Mounjaro.

Taste changes varied by drug. Twenty‑six percent of Wegovy users said food tasted saltier compared with 16.2 percent of Ozempic users and 15.2 percent of Mounjaro users. Reports of increased sweetness were similar across drugs: 21.7 percent for Mounjaro, 21.6 percent for Ozempic and 19.4 percent for Wegovy.

More than half of participants (58.4 percent) reported less hunger overall, with 61.2 percent of Ozempic users, 56.5 percent of Mounjaro users and 54.4 percent of Wegovy users reporting reduced hunger. Increased satiety — feeling full sooner after eating — was reported by two‑thirds of respondents, with 66.8 percent for Wegovy, 63.1 percent for Mounjaro and 58.8 percent for Ozempic. A larger share of Mounjaro users (41.3 percent) reported a strong reduction in food cravings than users of Wegovy (34.1 percent) or Ozempic (29.7 percent).

Further analysis identified associations between taste shifts and appetite markers. Participants who said sweetness had increased were about twice as likely to report feeling full sooner after a meal, 85 percent more likely to report fewer cravings and 67 percent more likely to report lower overall appetite. Those who reported increased saltiness were more than twice as likely to report earlier satiety.

When researchers adjusted for dose, age and sex, average body mass index declined by 17.4 percent among Ozempic users, 17.6 percent among Wegovy users and 15.5 percent among Mounjaro users. The investigators did not find a direct link between reported taste change and magnitude of BMI reduction.

Lead author Othmar Moser of the University of Bayreuth said the medications may affect taste by acting on taste‑bud cells and brain regions that process taste and reward. "This means they can subtly change how strong flavours, like sweetness or saltiness are perceived. This, in turn, may affect appetite," he said. The researchers suggested that monitoring patients for taste changes could provide clues about treatment response.

The investigators presented the findings at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, and the results were published in the journal Diabetes, Obesity and Metabolism.

The authors cautioned that the study relied on self‑reported measures and a convenience sample that may not represent all users of these medications, and that the design does not prove causation. They noted that taste changes are likely only one of many factors influencing weight loss, which also depends on long‑term eating patterns and physical activity.

The findings add to a growing body of research on glucagon‑like peptide‑1 (GLP‑1) agonists and related drugs that has documented effects on appetite and weight. A recent separate analysis reported weight loss and improved blood sugar control among children treated with such medications, but it also noted a higher incidence of gastrointestinal side effects including nausea, vomiting, diarrhea and constipation.

Clinicians and patients weighing the benefits and risks of GLP‑1 receptor agonists said the new data underline the range of physiological effects these drugs can have beyond calorie intake, and highlight the importance of monitoring side effects and patient experience during treatment.